4-Nitrophthalic acid is a metal-organic framework (MOF).

4-Methylbenzyl cyanide is an organic chemical probe used to study intramolecular rotation properties. 4-Methylbenzyl cyanide is promising for research of NMR spectroscopy and physical chemistry research on molecular dynamics.

4-Methyl-3-hydroxyanthranilic acid (MHA) is a key precursor for the synthesis of Actinomycin D.

4-Methoxyphthalic acid is a metal-organic framework (MOF).

4-Hydroxyphenylacetylglutamic acid is a metabolite of Morus alba L.

4-Hydroxyalprenolol (Alp2b) is a metabolite of β-receptor blocker Alprenolol.

4E,14Z-Sphingadiene is a sphosphingolipid.

3-Methylcathinone (3-MMC) hydrochloride is an analogue of a psychoactive substance.

349U85 hydrochloride is a vasodilator-cardiotonic agent.

2'-Deoxy-5-hydroxymethyl-CTP is a nucleoside metabolite.

22-Oxodocosanoic acid is a nucleoside metabolite.

1-Olein-2-myristin is an acylglycerol.

1-Laurin-2-olein is a glycerolipid.

1-Heptadecanoin-3-olein is an acylglycerol.

1-Arachidonin-2-palmitin-3-olein is an acylglycerol.

11,14,15-THETA (11,14,15-Trihydroxyeicosatrienoic acid) is a nucleoside metabolite.

1,3-Dibutyrin is a glycerolipid.

1,10-Bis(methylsulfinyl)decane (Compound IIf) is a decamethonium analogue and is a non-electrolytic sulfoxide compound. 1,10-Bis(methylsulfinyl)decane has low lethal (LD50 >37.5 mg/kg) effect in mice and neuromuscular blocking (ED50 >7 mg/kg) effects in cat.

(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib. (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia.

(R)-Ureidoisobutyric acid is a nucleoside metabolite.

(3S,5S)-3,5-Diaminohexanoate ((3S,5S)-DAH) is a nucleoside metabolite.

(2S)-2-Isopropyl-3-oxosuccinate ((2S)-2-Isopropyl-3-oxosuccinic acid) is a nucleoside metabolite.

Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, it demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies.

BSJ-5-63 is a potent PROTAC degrader of CDK12, CDK7, CDK9. BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K, while also suppressing the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 demonstrates anticancer properties and has the potential for the research of prostate cancer.

Camonsertib is a potent ATR inhibitor. ATR inhibitor 4 has antitumor activity.

Nedisertib (M3814, MSC2490484A) is a highly potent, selective, orally bioavailable inhibitor of DNA-PK.

Mal-Exatecan is a Mal (Maleimide) modified Exatecan. Rilpivirine is an effective and selective diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). It exhibits potent antiviral activity against both wild-type HIV (EC50 = 0.4 nM) and mutant strains (EC50 = 0.1-2.0 nM).

LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents.